Frontida BioPharm Inc., a pharmaceutical contract development and manufacturing organization (CDMO) based in the Philadelphia and Chicago areas, has appointed Praful Agrawala, Ph.D., as executive vice president, Technology. Agrawala adds years of pharmaceutical product development leadership experience to Frontida after serving in executive roles at Amneal Pharmaceuticals, Sanofi-Aventis, and Schering-Plough Research Institute.
 
Agrawala’s core competencies include product development, discovery research interfacing, preclinical evaluation, clinical and CMC development of new chemical entities, inhalation product development, drug-device combinations development, manufacturing process development and commercialization, contract development & manufacturing, licensing, alliance management and platform technology evaluations.
 
Experience
 
Agrawala joins Frontida with a noteworthy scientific background including experience in multiple dosage form development of long-acting injectables, sterile solutions, MDI and DPI inhalation products and devices, modified release tablets, rapidly disintegrating tablets, oral and nasal suspensions, oral solutions, semi-solids and transdermal products.
 
Anthony Qu, Frontida’s COO, commented, “Dr. Agrawala’s proven track record in developing complex formulations of long-acting and immediate release injectables, inhalation and oral dosage forms showcases his extensive background in pharmaceutics, quality and regulatory aspects of branded and generic product development. Our team is excited to have Dr. Agrawala join us during this intensive growth phase at Frontida.”
 
In response, Dr. Agrawala said, “I am delighted to join Frontida Biopharm at this time of tremendous growth for the company. I look forward to working with the teams at Frontida to advance the company’s broad portfolio of drug delivery technologies, product development and manufacturing services for pharmaceutical companies.”